Introducing Black Swan Biotech (BSB), a Perth based biotechnology company dedicated to developing advanced Antisense Oligonucleotides (AOs) for Motor Neuron Disease (MND), with a focus on Amyotrophic Lateral Sclerosis (ALS). Leveraging cutting-edge genomic research, BSBH aims to create highly targeted therapies addressing the genetic drivers of MND. Our mission is to provide effective, precision-based gene modulating therapies to improve the lives of those affected by MND.